Physicians' Academy for Cardiovascular Education
Member

PCSK9 inhibitors: From bench to bedside

Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA

Lowering LDL-c for a longer period of time really matters

Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA

No J-shaped curve for efficacy in PCSK9 outcome trials

Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 outcome trials: The results put into perspective of other clinical developments

Mar. 19, 2017 - Prof. Peter Sever - London, United Kingdom - ACC 2017, Washington DC, USA

LDL lowering for CVD prevention: From hypothesis to axiom

Mar. 19, 2017 - Prof. John JP Kastelein - Amsterdam, The Netherlands - ACC 2017, Washington DC, USA

Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?

Mar. 18, 2017 - Prof. John Chapman - Paris, France - ACC 2017, Washington DC, USA

Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time

Mar. 17, 2017

CV outcomes with a PCSK9 inhibitor: FOURIER study

Mar. 16, 2017

Careful implementation of PCSK9 inhibitors in clinical practice

Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)

Promising results in pivotal trials of novel lipid-modifying drugs

Dec. 12, 2016 - Amsterdam, The Netherlands - Prof. John JP Kastelein, MD (AMC Amsterdam, The Netherlands)

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada
##SCROLLER_ITEMS_FULL_TITLE##

New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study

Nov. 22, 2016 - Kausik Ray, MD - Imperial College London, United Kingdom
##SCROLLER_ITEMS_FULL_TITLE##

Brief update on various pharmacotherapeutic strategies to lower CV risk

Nov. 21, 2016 - AHA 2016 - Prof. Wouter Jukema, MD (LUMC Leiden, The Netherlands)
##SCROLLER_ITEMS_FULL_TITLE##

PCSK9 inhibitor on top of statin therapy gives additional atheroma volume regression

Nov. 21, 2016 - AHA 2016 - Steve Nissen, MD (Cleveland Clinic, Cleveland, OH, USA)
##SCROLLER_ITEMS_FULL_TITLE##

Frequency apheresis lowered in FH patient receiving PCSK9-inhibiting treatment

Oct. 4, 2016 - ESC - 2016 Rome - Prof Patrick M Moriarty, MD (University of Kansas Medical Center, KS, USA)

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

A clinical perspective on PCSK9 inhibition: What do we know an what can we expect?

Aug. 27, 2016 - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

PCSK9, the short track road from discovery as drug target towards the clinic

Aug. 27, 2016 - ESC 2016, Rome - Gilles Lambert, MD – Université de la Réunion, Sainte-Clotilde, France

Role of PCSK9 in the regulation of LDL cholesterol

Sep. 12, 2016

LDL cholesterol, the LDL receptor pathway & PCSK9

Sep. 10, 2016

The future perspectives for care for patients with high Lp(a)

May 27, 2016 - Innsbruck, Germany - Prof. Erik Stroes, MD PhD – Academic Medical Center, Amsterdam, The Netherlands - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands

Steps forward in lipid-lowering therapy

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Robert P. Giugliano, MD - Boston, MA, USA
##SCROLLER_ITEMS_FULL_TITLE##

GAUSS-3: Statin intolerance a real problem and PCSK9 inhibition with evolocumab effective

Apr. 3, 2016 - ACC 2016, Chicago - Steven L Nissen
##SCROLLER_ITEMS_FULL_TITLE##

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt
##SCROLLER_ITEMS_FULL_TITLE##

Impacting lipid disorders through personalised healthcare

Feb. 2, 2016 - VBWG, Orlando - Daniel J. Rader, M.D.
##SCROLLER_ITEMS_FULL_TITLE##

Accumulating clinical data on PCSK9 inhibition: What are the key lessons?

Sep. 30, 2015 - ESC 2015 London - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
##SCROLLER_ITEMS_FULL_TITLE##

Lipid Management 2020: A glance at the future

Sep. 24, 2015
##SCROLLER_ITEMS_FULL_TITLE##

Patients confident to use injectable PCSK9-inhibitor via self-injection

May 25, 2015 - ISA2015, Amsterdam - Bertrand Cariou

PCSK9 inhibitors: From bench to bedside

Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA
Prof. Gilles Lambert describes the development since the discovery in 2002 of PCSK9 until the results of outcome trials with a PCSK9 inhibitor in 2017.

PCSK9 Expert Opinions Prof. Gilles Lambert describes the development of PCSK9 inhibitors since the discovery in 2002 of PCSK9 as a circulating protein targeting the LDL receptor for degradation. Now in 2017, results of outcome trials with a PCSK9 inhibitor are available.

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA
Prof. Stephen Nicholls argues that the PCSK9 outcome trials reinforce the concept that patients with high CV risk may benefit from PCSK9 inhibiting treatment.

PCSK9 Expert Opinions By combining all recent insights on treatment with PCSK9 inhibitors, prof. Stephen Nicholls argues that the PCSK9 outcome trials reinforce the concept that patients with high CV risk may benefit from PCSK9 inhibiting treatment.

Lowering LDL-c for a longer period of time really matters

Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA
Dr. Paul M. Ridker states that further lowering of LDL-c during a longer period of time safely translates into lower rates of CVD.

PCSK9 Expert Opinions Dr. Paul M. Ridker states that from FOURIER and SPIRE it becomes clear that further lowering of LDL-c during a longer period of time safely translates into lower rates of CVD.

No J-shaped curve for efficacy in PCSK9 outcome trials

Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA
Prof. Kausik Ray describes the absence of a  J-shaped curve in the PCSK9 outcome trials,  meaning there is no apparent diminution of benefit to very low LDL.

PCSK9 Expert Opinions Prof. Kausik Ray describes the practical implications of the PCSK9 outcome trials. In terms of efficacy, there is no J-shaped curve, meaning there is no apparent diminution of benefit to very low LDL

PCSK9 outcome trials: The results put into perspective of other clinical developments

Mar. 19, 2017 - Prof. Peter Sever - London, United Kingdom - ACC 2017, Washington DC, USA
Prof. Peter Sever describes the results of the FOURIER with respect to safety and efficacy and puts the data into perspective of other trials and molecules.

PCSK9 Expert Opinions Prof. Peter Sever describes the results of the FOURIER with respect to safety and efficacy. He puts the data into perspective of other trials and molecules.

Long-term PCSK9 inhibition consistently lowers LDL-C in open-label extension study

Results Up to 4 Years From the Open-Label OSLER-1 Extension Study

Apr. 4, 2017 - Koren MJ, et al. - JAMA Cardiol 2017

PCSK9 antibody evolocumab consistently lowered LDL-C levels for an average of 44 months in a diverse patient population with hypercholesterolemia, and was well tolerated.

LDL lowering for CVD prevention: From hypothesis to axiom

Mar. 19, 2017 - Prof. John JP Kastelein - Amsterdam, The Netherlands - ACC 2017, Washington DC, USA
Prof. John Kastelein argues that after FOURIER and SPIRE 1&2, there can no longer be any doubt that lowering LDL is crucial for CVD prevention.

PCSK9 Expert Opinions Prof. John Kastelein explains the most important points from FOURIER and SPIRE 1&2. He argues that there can no longer be any doubt that lowering LDL is crucial for CVD prevention.

Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?

Mar. 18, 2017 - Prof. John Chapman - Paris, France - ACC 2017, Washington DC, USA
Prof. John Chapman gives his personal views on the results of FOURIER and SPIRE 1&2 and the implications for LDL-c lowering in high-CV risk individuals.

PCSK9 Expert Opinions Prof. John Chapman gives his personal views on the results of FOURIER and SPIRE 1&2. Key question is whether in the light of the new data, the LDL-c goal will be maintained or lowered in high-CV risk individuals.

Antidrug antibodies against PCSK9 antibody did not affect efficacy and safety

Letter to the editor

Mar. 22, 2017 - Roth EM, et al. - NEJM, 2017

In ODYSSEY trials, LDL-lowering and adverse events were not different between patients with and without antidrug antibodies against PCSK9 antibody alirocumab.

No effect of PCSK9 inhibitor on cognitive functioning in CVD patients, even at LDL-c <25 mg/dL

Presented at ACC.17 by Robert P. Giugliano

Mar. 18, 2017 - news

ACC 2017 No difference in cognitive function was seen between evolocumab and placebo-treated patients in the EBBINGHAUS trial. No cognitive decline was seen over time in either treatment group.

Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time

Mar. 17, 2017
Dr. Paul Ridker discusses data of the SPIRE studies into use of the PCSK9 antibody bococizumab, including the unexpected attenuation of the LDL-c response over time in some patient, as a consequence of development of antibodies against the drug.

ACC 2017 Dr. Paul Ridker discusses data of the SPIRE studies into use of the PCSK9 antibody bococizumab, including the unexpected attenuation of the LDL-c response over time in some patients, as a consequence of development of antibodies against the drug.

Sustained LDL-c lowering up to 360 days with siRNA directed against PCSK9 in phase 2 study

Presented at ACC.17 by Kausik Ray

Mar. 16, 2017 - news

ACC 2017 Inclisiran, which prevents PCSK9 protein production, resulted in long-term LDL-c lowering after two doses of siRNA, without safety concerns, in the ORION-1 study.

3' education

Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time

Mar. 17, 2017

CV outcomes with a PCSK9 inhibitor: FOURIER study

Mar. 16, 2017

Promising results in pivotal trials of novel lipid-modifying drugs

Dec. 12, 2016 - Amsterdam, The Netherlands - Prof. John JP Kastelein, MD (AMC Amsterdam, The Netherlands)

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada

New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study

Nov. 22, 2016 - Kausik Ray, MD - Imperial College London, United Kingdom
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Brief update on various pharmacotherapeutic strategies to lower CV risk

Nov. 21, 2016 - AHA 2016 - Prof. Wouter Jukema, MD (LUMC Leiden, The Netherlands)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

PCSK9 inhibitor on top of statin therapy gives additional atheroma volume regression

Nov. 21, 2016 - AHA 2016 - Steve Nissen, MD (Cleveland Clinic, Cleveland, OH, USA)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Frequency apheresis lowered in FH patient receiving PCSK9-inhibiting treatment

Oct. 4, 2016 - ESC - 2016 Rome - Prof Patrick M Moriarty, MD (University of Kansas Medical Center, KS, USA)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Steps forward in lipid-lowering therapy

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Robert P. Giugliano, MD - Boston, MA, USA

GAUSS-3: Statin intolerance a real problem and PCSK9 inhibition with evolocumab effective

Apr. 3, 2016 - ACC 2016, Chicago - Steven L Nissen
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Impacting lipid disorders through personalised healthcare

Feb. 2, 2016 - VBWG, Orlando - Daniel J. Rader, M.D.
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Patients confident to use injectable PCSK9-inhibitor via self-injection

May 25, 2015 - ISA2015, Amsterdam - Bertrand Cariou
##RIGHT_SECTION_ITEMS_FULL_TITLE##

CETP-inhibitor reduces non-HDL-c and PCSK9 in animal model

May 24, 2015 - ISA2015, Amsterdam - Dr. Yanan Wang
##RIGHT_SECTION_ITEMS_FULL_TITLE##

The effects of a PCSK9-inhibitor on various lipid fractions

May 24, 2015 - ISA2015, Amsterdam - Gisette Reyes-Soffer
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Homozygous FH: treatment challenges

May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Frederick Raal
##RIGHT_SECTION_ITEMS_FULL_TITLE##

PCSK9-inhibitor less frequently administered may be effective treatment option

June 15, 2015 - ISA Amsterdam - Prof. Eli Roth
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Large pooled analysis reveals no safety concerns with PCSK9-inhibitor

June 16, 2015 - ISA2015, Amsterdam - Jennifer Robinson
##RIGHT_SECTION_ITEMS_FULL_TITLE##

TAUSSIG: clinically relevant LDL-lowering in difficult to treat patients

June 15, 2015 - ISA2015, Amsterdam - Prof. Frederick Raal
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Lipids: Who is at real high risk?

May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof Kausik Ray
##RIGHT_SECTION_ITEMS_FULL_TITLE##

OSLER studies Compelling data on PCSK9 inhibition

Mar. 15, 2015 - ACC 2015, San Diego - Marc Sabatine, MD Boston
##RIGHT_SECTION_ITEMS_FULL_TITLE##

OSLER 1 & 2: Long term efficacy and safety outcomes PCSK9 inhibition

Mar. 16, 2015 - ACC 2015, San Diego - Prof.dr. John Kastelein
##RIGHT_SECTION_ITEMS_FULL_TITLE##

2014: the major lipid developments in review

Dec. 20, 2014 - Amsterdam - Prof. John JP Kastelein
##RIGHT_SECTION_ITEMS_FULL_TITLE##

IMPROVE-IT: Implications for clinical practice & guidelines

Nov. 19, 2014 - Chicago, Il, USA - Prof. Kausik Ray
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Confirmation LDL-c lowering beyond current borders with non statin therapy is effective

Nov. 19, 2014 - Chicago, Il, USA - Prof Erik Stroes
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Potential role of PCSK9 inhibitors

Nov. 26, 2014 - VBWG Chicago - Michael J Koren
##RIGHT_SECTION_ITEMS_FULL_TITLE##

PCSK9 inhibition: Clinical Update 2014

Oct. 29, 2014 - Snapshot 2014 - Dr Evan Stein
##RIGHT_SECTION_ITEMS_FULL_TITLE##

HoFH: New insights in prevalence and therapy

Oct. 26, 2014 - Snapshot 2014 - dr Kees Hovingh
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Is inflammation reduction key for targeting residual risk, beyond lowering LDL-c?

Oct. 18, 2014 - Snapshot 2014 - Prof. Paul M Ridker, MD
##RIGHT_SECTION_ITEMS_FULL_TITLE##

IMPROVE-IT: Scenarios for understanding the results

Sep. 9, 2014 - Barcelona - Prof Chris Packard
##RIGHT_SECTION_ITEMS_FULL_TITLE##

LDL cholesterol, LDL receptor & PCSK9

July 31, 2013
##RIGHT_SECTION_ITEMS_FULL_TITLE##

LDL Receptor Function and Life Cycle

Dec. 27, 2013
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Targeting fasting and post-prandial triglycerides

Sep. 1, 2013 - Snapshot 2013 - Dr. Joanne M. Donovan
##RIGHT_SECTION_ITEMS_FULL_TITLE##

PCSK9 & LDL- The best story of translational medicine?

Sep. 8, 2013 - Amsterdam, August 31, 2013 - Dr Evan Stein
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Treating the untreatable high LDL-c

June 17, 2013 - Kuala Lumpur - Dato' dr Khoo Kah Lin
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Antibodies against PCSK9: A new LDL-c lowering therapy?

Mar. 31, 2013 - CVC 2013 - Dr. Kees Hovingh, Amsterdam
##RIGHT_SECTION_ITEMS_FULL_TITLE##

10' education

PCSK9 inhibitors: From bench to bedside

Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA

Lowering LDL-c for a longer period of time really matters

Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA

No J-shaped curve for efficacy in PCSK9 outcome trials

Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 outcome trials: The results put into perspective of other clinical developments

Mar. 19, 2017 - Prof. Peter Sever - London, United Kingdom - ACC 2017, Washington DC, USA

LDL lowering for CVD prevention: From hypothesis to axiom

Mar. 19, 2017 - Prof. John JP Kastelein - Amsterdam, The Netherlands - ACC 2017, Washington DC, USA

Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?

Mar. 18, 2017 - Prof. John Chapman - Paris, France - ACC 2017, Washington DC, USA

Careful implementation of PCSK9 inhibitors in clinical practice

Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

A clinical perspective on PCSK9 inhibition: What do we know an what can we expect?

Aug. 27, 2016 - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

PCSK9, the short track road from discovery as drug target towards the clinic

Aug. 27, 2016 - ESC 2016, Rome - Gilles Lambert, MD – Université de la Réunion, Sainte-Clotilde, France

The future perspectives for care for patients with high Lp(a)

May 27, 2016 - Innsbruck, Germany - Prof. Erik Stroes, MD PhD – Academic Medical Center, Amsterdam, The Netherlands - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Accumulating clinical data on PCSK9 inhibition: What are the key lessons?

Sep. 30, 2015 - ESC 2015 London - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Lipid Management 2020: A glance at the future

Sep. 24, 2015
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Critique on the new AHA / ACC guidelines for lipid management

Nov. 7, 2014 - Barcelona, ESC - Prof Kausik Ray, Imperial College London, United KIngdom
##RIGHT_SECTION_ITEMS_FULL_TITLE##

HoFH: New insights and expanding therapeutic options

Sep. 6, 2014 - Snapshot 2014 - Dr. Kees Hovingh, AMC, Amsterdam, The Netherlands
##RIGHT_SECTION_ITEMS_FULL_TITLE##

PCSK9 inhibition: Novel insights into a new therapeutic approach for the lowering of LDL-C: the PCSK9 saga

Sep. 3, 2014
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Biology and validation of PCSK9 as a novel target to lower LDL-C

Aug. 30, 2014 - Barcelona, ESC - Prof. John JP Kastelein
##RIGHT_SECTION_ITEMS_FULL_TITLE##

PCSK9: The promise of a new target in lipid management

Sep. 3, 2014 - Barcelona, ESC - Prof. John E Deanfield, UCL, London
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Emerging therapies to lower LDL-cholesterol

May 8, 2014
##RIGHT_SECTION_ITEMS_FULL_TITLE##

PCSK9: the new lipid target in preventive cardiology?

Sep. 26, 2013

The roadmap of PCSK9 inhibitors towards the clinic

Sep. 30, 2013
##RIGHT_SECTION_ITEMS_FULL_TITLE##

PCSK9 inhibition: Mechanistic insights into a new therapeutic approach for the lowering of LDL-c

Sep. 30, 2013
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Monoclonal antibodies that target PCSK9: What the first clinical trial data are telling?

Sep. 30, 2013
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Familial Hypercholesterolemia: Why are we not reaching goals in these patients?

Sep. 30, 2013
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Lowering of LDL-C: Novel concepts and novel promises

Sep. 14, 2013
##RIGHT_SECTION_ITEMS_FULL_TITLE##